ArticleFrontiers in oncology2026
Clinicopathological and preoperative biomarkers associated with recurrence after primary surgical treatment for endometrial cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative recurrence remains a major concern in endometrial cancer (EC), and routinely available preoperative biomarkers may complement established clinicopathological factors. This study aimed to evaluate the associations of preoperative neutrophil-to-lymphocyte ratio (NLR), fibrinogen (FIB), and serum cancer antigen 125 (CA125) with recurrence after primary surgical treatment for EC. Methods: This single-center retrospective cohort included 368 patients treated between January 2019 and December 2024. Cohort-specific biomarker thresholds were derived by receiver operating characteristic analysis using the maximum Youden index. Multivariable logistic regression evaluated associations with recurrence after adjustment for International Federation of Gynecology and Obstetrics (FIGO) stage, histological type, and myometrial invasion. Sensitivity analyses, recurrence-free survival analysis, Firth penalized regression, and bootstrap internal validation were also performed. Results: During a median follow-up of 30 months, 32 patients (8.7%) experienced recurrence. Recurrence was associated with NLR >2.16 (odds ratio [OR], 4.03; 95% confidence interval [CI], 1.40-11.63), FIB >3.38 g/L (OR, 3.55; 95% CI, 1.30-9.67), CA125 >18.06 U/mL (OR, 2.52; 95% CI, 1.25-5.07), FIGO stage III disease (OR, 3.73; 95% CI, 1.45-9.59), non-adenocarcinoma histology (OR, 3.28; 95% CI, 1.35-7.96), and myometrial invasion ≥1/2 (OR, 3.01; 95% CI, 1.30-6.96). After Bonferroni correction, only FIGO stage III remained significant, whereas all six variables met the Benjamini-Hochberg false discovery rate threshold. The areas under the curve were 0.714 for NLR, 0.658 for FIB, and 0.765 for CA125. The optimism-corrected C-statistic was 0.835. Conclusion: Preoperative NLR, FIB, and CA125 were associated with postoperative recurrence and may provide complementary information to clinicopathological factors. The cohort-specific thresholds require external validation in larger multicenter studies before clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.